Resources
-
Key Principles and Lifecycle Considerations for Pharmacopoeial Analytical Procedures
Speaker Presentation: CMC Strategy Forum Europe 2025
Buda Mihaela, European Directorate for the Quality of Medicines & Healthcare, 2025 -
In Vitro/in Vivo/in Silico Models to Support Bridging Strategies From SC to SC, From IV to SC and Vice Versa
Speaker Presentation: CMC Strategy Forum Europe 2025
Bruin Gerard, Novartis AG, 2025 -
Platform Method Applications – Leveraging Knowledge and Addressing Challenges
Speaker Presentation: CMC Strategy Forum Europe 2025
Bora Karina, Lonza Biologics, 2025 -
General Principles for Life-Cycle Management of Reference Standards
Speaker Presentation: CMC Strategy Forum Europe 2025
Bobinnec Yves, IPSEN, 2025 -
Prior and Platform Knowledge Use (Specifically Through a PTMF) in EU/EEA
Speaker Presentation: CMC Strategy Forum Europe 2025
Bilanin Mihai, GlaxoSmithKline, 2025 -
It’s All About Consistency: Change of Reference Standards for Potency Assessment in Clinical Phases
Speaker Presentation: CMC Strategy Forum Europe 2025
Beck Hermann, F. Hoffmann-La Roche Ltd., 2025 -
Subcutaneous Biologics: Advancing High-Concentration Technologies and Justifying CQA Specification Limits Through Translational Immunogenicity Models – Status Update
Speaker Presentation: CMC Strategy Forum Europe 2025
Bechtold-Peters Karoline, Novartis Pharma AG, 2025 -
ADCs and AxCs: Summary of a Recent EFPIA Member Survey on Antibody Conjugates
Speaker Presentation: CMC Strategy Forum Europe 2025
Bechtold-Peters Karoline, Novartis Pharma AG, 2025 -
Revolutionizing Regulatory Submissions Through Digital Innovation
Speaker Presentation: CMC Strategy Forum Europe 2025
Abernathy Michael, Amgen Inc., 2025 -
CMC Strategy Forum Europe 2025 Scientific Program
Scientific Program: CMC Strategy Forum Europe 2025
-
CMC Strategy Forum Europe 2025 Summary Infographic
Summary Infographic: CMC Strategy Forum Europe 2025
-
Streamlining Agile MS Workflows
with Genedata
Speaker Presentation: Mass Spec 2025
Cazy Aaron, Eli Lilly and Company, 2025 -
New Paradigm for Charge Variant Characterization Utilizing 'Discovery' Assisted Fractionation Strategy
Speaker Presentation: Mass Spec 2025
Xiao Yongsheng, WuXi Biologics, 2025 -
Mechanistic Insights into non-mAb Aggregation Using MS-Cleavable Linker
Speaker Presentation: Mass Spec 2025
Whitty-Léveillé Laurence, Merck & Co., Inc., 2025 -
Applications of Mass Spectrometry in Biopharmaceutical Discovery: From Small Molecules to Proteins
Speaker Presentation: Mass Spec 2025
Sahasrabuddhe Aniruddha, Amgen Inc., 2025 -
Automation and HTP Mass Spectrometry to Accelerate Biotherapeutics Discovery
Speaker Presentation: Mass Spec 2025
Pomerantz Steven C, Johnson & Johnson, 2025 -
Diving Into the Complexities of Non-Natural Amino Acid Antibodies with Innovating Mass Spectrometry Approaches
Speaker Presentation: Mass Spec 2025
Nanda Hirsh, Johnson & Johnson, 2025 -
A Robust and Versatile New Peak Detection Workflow to Facilitate the Implementation of the LC-MS Multi-Attribute Method (MAM) from Research to Commercialization
Speaker Presentation: Mass Spec 2025
Merkle Patrick, Novartis Pharma AG, 2025 -
Monitoring Intact AAV and AAV Building Blocks Through Individual Ion Mass Spectrometry
Speaker Presentation: Mass Spec 2025
McGee Jack, ImmPro, Inc., 2025 -
Evaluating Antigen-Antibody Interactions: A Comparative Study of Higher-Order Structural MS Methods
Speaker Presentation: Mass Spec 2025
Ma Yiran Silvia, Eli Lilly and Company, 2025